Nasal Pharmaceutical Composition Treats Chronic Rhinosinusitis

← USPTO Patent Applications

TOPICAL NASAL PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF CHRONIC RHINOSINUSITIS (CRS)

Application US20260108489A1 Kind: A1 Apr 23, 2026

Inventors

Eduardo Roberto Varizat, Daniel Roberto Varizat

Abstract

The invention relates to a new topical nasal pharmaceutical composition for the treatment and prophylaxis of Rhinosinusitis (RS), comprising a homogeneous aqueous suspension with a therapeutically effective amount of the following well-known active ingredients: Rifamycin, an antibiotic and anti-inflammatory agent for topical or local use; fluticasone propionate, an anti-inflammatory agent for local use; optionally, oxymetazoline hydrochloride, a decongestant; and bacterial antigens, local immunostimulants; 0.9% saline solution, a vehicle; and pharmaceutically acceptable excipients q.s., which are formulated for topical administration via nasal spray. The combination of these compounds produces synergy, resulting in a greater local antibiotic, anti-inflammatory, decongestant and immunomodulatory effect at the specific site of action. Its effectiveness in chronic rhinosinusitis is particularly notable in low doses. So is its good tolerance, absence of adverse effects, and ease of application. No rebound congestion has been reported with prolonged use.

CPC Classifications

A61K 31/395 A61K 9/0043 A61K 9/08 A61K 31/4174 A61K 31/56 A61K 39/0208 A61K 39/0266 A61K 39/092 A61K 39/102 A61P 31/04 A61P 37/04

Filing Date

2025-10-15

Application No.

19359380

View original document →